Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Freeline

- PMLiVE

Celgene says no to Mereo’s cancer drug etigilimab

UK biotech will focus on rare disease drugs

- PMLiVE

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs

- PMLiVE

Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst

Move cuts pipeline depth, says GlobalData

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

RNA-focused biotech Storm Therapeutics raises extra £14m

New head of translational oncology also hired

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Syncona launches another cell therapy company, Treg specialist Quell

Focuses on novel immune system approach

- PMLiVE

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

'Basecamp' will provide expertise and labs to launch multiple firms

- PMLiVE

Tax credit changes could put a ‘hard brake’ on UK biotech

Anti-fraud measures will hit genuine firms, fears BIA

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links